Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5939
    +0.0004 (+0.07%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • OIL

    83.43
    +0.07 (+0.08%)
     
  • GOLD

    2,335.80
    -6.30 (-0.27%)
     

How Analysts View Tetraphase Pharmaceuticals in April 2018

How Analysts View Tetraphase Pharmaceuticals in April 2018

Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.